search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
ARMY AL&T


SUCCESS ON STAGE


JA2’s diligent efforts to procure vaccines, therapeutics and enablers have been critical to the nation. (Photo by U.S. Air Force Staff Sgt. K. Tucker Owen)


acquisition and life cycle management of chemical-biological defense medical coun- termeasure programs and protective gear for the warfighter.


Many of the experts from these offices were quickly detailed to support the global response in partnership with HHS and DOD’s joint mission, the Countermea- sures Acceleration Group. Additionally, members of the JPEO-CBRND team were simultaneously supporting the COVID- 19 acquisition needs of Defense Health Agency and DOD Health Affairs. Most of these individuals were tasked with dual mission sets—supporting the most press- ing COVID-19 vaccine and therapeutics


research and development needs, while still trying to keep up with their day jobs—managing programs of record for CBRND project portfolios that provide protection for the warfighter. As time went on, it became clear that a dedicated team was needed to oversee acquisitions efforts from cradle to grave if the government were to procure and distribute a suit- able quantity of vaccine and treatment doses. JA2’s vaccines, therapeutics and enablers team provided the link between DOD contracting and HHS, employing agile acquisition efforts for getting over two billion vaccine doses on contract and allowing acceptance of the first one billion vaccine doses domestically.


Te vaccines, therapeutics and enablers team is made up of individuals who are dedicated to helping with the early devel- opment, procurement and delivery of more than one billion COVID-19 vaccine doses. Tese efforts directly support the ongo- ing frontline response to the pandemic. Because of that team’s work for the past two-plus years, HHS’ Biomedical Advanced Research Authority recently accepted its billionth vaccine dose for distribution.


Without the vaccines, therapeutics and enablers team, this milestone would not have been possible. Deputy vaccines, ther- apeutics and enablers lead Breena Berté


https://asc.ar my.mil


71


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116  |  Page 117  |  Page 118  |  Page 119  |  Page 120  |  Page 121  |  Page 122